Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Total Assets : $48.94 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Total Assets?

Clarus Therapeutics Holdings's Total Assets for the quarter that ended in Jun. 2022 was $48.94 Mil.

Total Assets is connected with ROA %. Clarus Therapeutics Holdings's annualized ROA % for the quarter that ended in Jun. 2022 was -100.11%. Total Assets is also linked to Revenue through Asset Turnover. Clarus Therapeutics Holdings's Asset Turnover for the quarter that ended in Jun. 2022 was 0.09.

Clarus Therapeutics Holdings Total Assets Historical Data

The historical data trend for Clarus Therapeutics Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Total Assets Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Total Assets

19.40

51.71

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Assets	Get a 7-Day Free Trial			-	45.32	51.71	36.52	48.94

Clarus Therapeutics Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Clarus Therapeutics Holdings's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	-15.919	+	67.627
	=	51.71

Clarus Therapeutics Holdings's Total Assets for the quarter that ended in Jun. 2022 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2022 )	+	Total Liabilities (Q: Jun. 2022 )
	=	-13.063	+	62.003
	=	48.94

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Total Assets Explanation

Total Assets is connected with ROA %.

Clarus Therapeutics Holdings's annualized ROA % for the quarter that ended in Jun. 2022 is

ROA %	=	Net Income (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
	=	-42.776	/	( (36.522	+	48.94)	/ 2 )
	=	-42.776	/	42.731
	=	-100.11 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Clarus Therapeutics Holdings's Asset Turnover for the quarter that ended in Jun. 2022 is

	Asset Turnover
=	Revenue (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
=	4.05	/	( (36.522	+	48.94)	/ 2 )
=	4.05	/	42.731
=	0.09

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Clarus Therapeutics Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402